Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 4/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18597586 | 1.00 | TYMS (0.66) | TYMS | |
| SCHEMBL12123754 | 0.92 | TYMS (0.58) | TYMS | |
| SCHEMBL7269671 | 0.91 | TYMS (0.62) | TYMS | |
| SCHEMBL7269665 | 0.91 | TYMS (0.62) | TYMS | |
| SCHEMBL15115324 | 0.90 | TYMS (0.67) | TYMS | |
| SCHEMBL8694412 | 0.90 | TYMS (0.67) | TYMS | |
| SCHEMBL4277814 | 0.90 | TYMS (0.67) | TYMS | |
| SCHEMBL3345587 | 0.89 | TYMS (0.66) | TYMS | |
| SCHEMBL13258615 | 0.88 | TYMS (0.56) | TYMS | |
| SCHEMBL4274515 | 0.87 | TK1 (0.66) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1167972-B1 | Enzyme catalyzed therapeutic agents | KIADIS PHARMA INTELLECTUAL PROPERTY B V (NL) | 2017-03-08 | — | — | EP | disclosed |
| US-7605144-B2 | Enzyme catalyzed therapeutic compounds | CELMED ONCOLOGY (USA), INC. (CA) | 2009-10-20 | — | — | US | disclosed |
| US-7601703-B2 | Enzyme catalyzed therapeutic agents | CELMED ONCOLOGY (USA), INC. (CA) | 2009-10-13 | — | — | US | disclosed |
| EP-1200455-B1 | ENZYME CATALYZED THERAPEUTIC ACTIVATION | CELMED ONCOLOGY USA INC (CA) | 2009-04-22 | — | — | EP | disclosed |
| US-7419968-B1 | Methods for treating therapy-resistant tumors | CELMED ONCOLOGY (USA), INC. (CA) | 2008-09-02 | — | — | US | disclosed |
| US-20040077588-A1 | Enzyme catalyzed therapeutic compounds | CELMED ONCOLOGY (USA), INC. (CA) | 2004-04-22 | — | — | US | disclosed |
| US-6683061-B1 | 1-(2,3-DIHYDROXYTETRAHYDROFURAN-5-YL)-5-(4-BROMO-1,3-BUTADIENYL) -PYRIMIDINE-2,4(1H,3H)-DIONE; ANTIPROLIFERATION AGENT | NEWBIOTICS, INC. | 2004-01-27 | — | — | US | disclosed |
| US-20020147175-A1 | Synergistic ECTA compositions | NEWBIOTICS, INC. | 2002-10-10 | — | — | US | disclosed |
| EP-1202749-A2 | ENZYME CATALYZED ANTI-INFECTIVE THERAPEUTIC AGENTS | Newbiotics, Inc. (US) | 2002-05-08 | — | — | EP | disclosed |
| EP-1045897-B1 | ENZYME CATALYZED THERAPEUTIC AGENTS | NEWBIOTICS INC (US) | 2002-01-30 | — | — | EP | disclosed |
| US-6339151-B1 | FORMING COMPOUNDS USING A NUCLEIC ACID BASE WITH A PHOSPHOROUS HALIDE TO FORM DRUGS FOR NONPROLIFERATION OF CELLS | NEWBIOTICS, INC. | 2002-01-15 | — | — | US | disclosed |
| EP-1167972-A2 | Enzyme catalyzed therapeutic agents | Newbiotics Inc. (US) | 2002-01-02 | — | — | EP | disclosed |
| US-20010034440-A1 | Enzyme catalyzed therapeutic agents | KIADIS PHARMA INTELLECTUAL PROPERTY B.V. (NL) | 2001-10-25 | — | — | US | disclosed |
| US-6245750-B1 | THYMIDINE PHOSPHORAMIDE DERIVATIVE; ANTIPROLIFERATIVE, ANTICARCINOGENIC AGENTS; ENZYME INHIBITORS; | NEWBIOTICS, INC. | 2001-06-12 | — | — | US | disclosed |
| WO-2001007087-A2 | ENZYME CATALYZED ANTI-INFECTIVE THERAPEUTIC AGENTS | NEWBIOTICS, INC. (US) | 2001-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034440-A1 | Enzyme catalyzed therapeutic agents | DNPEP, AGBL2, ENTPD2 | TYMS 194/4885 |
| US-20020147175-A1 | Synergistic ECTA compositions | ENTPD1, ENTPD2, ENPP1 | TYMS 72/4885 |
| US-20040077588-A1 | Enzyme catalyzed therapeutic compounds | RNASE1, QTRT1, FAP | TYMS 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.